Scancell Holdings plc (AIM:SCLP)
12.50
0.00 (0.00%)
At close: Feb 12, 2026
Scancell Holdings Revenue
Scancell Holdings had revenue of 4.71M GBP in the twelve months ending October 31, 2025. In the fiscal year ending April 30, 2025, Scancell Holdings had annual revenue of 4.71M.
Revenue
4.71M
Revenue Growth
n/a
P/S Ratio
27.54
Revenue / Employee
78.52K
Employees
60
Market Cap
129.72M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Apr 30, 2025 | 4.71M | - | - |
| Apr 30, 2024 | - | - | - |
| Apr 30, 2023 | 5.27M | - | - |
| Apr 30, 2022 | - | - | - |
| Apr 30, 2021 | - | - | - |
| Apr 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| hVIVO | 54.47M |
| Bioventix | 13.12M |
| PureTech Health | 4.66M |
| SkinBioTherapeutics | 4.64M |
| 4basebio | 1.78M |
| Ondine Biomedical | 1.18M |
| Avacta Group | 113.00K |
| ImmuPharma | -69.96K |
Scancell Holdings News
- 14 days ago - Scancell Holdings plc (SCNLF) Q2 2026 Earnings Call Transcript - Seeking Alpha
- 14 days ago - Scancell Holdings PLC (SCNLF) (Half Year 2026) Earnings Call Highlights: Regulatory Milestones ... - GuruFocus
- 14 days ago - Half Year 2026 Scancell Holdings PLC Earnings Call Transcript - GuruFocus
- 14 days ago - Scancell Holdings plc 2026 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 14 days ago - Scancell Holdings plc GAAP EPS of -£0.64p - Seeking Alpha
- 14 days ago - Interim Results for the six months ended 31 October 2025 - Benzinga
- 17 days ago - Scancell announces FDA clearance of IND application for global Phase 3 trial of iSCIB1+ in advanced melanoma - GlobeNewsWire
- 2 months ago - Scancell Holdings plc (SCNLF) Discusses SCOPE Phase II Data: iSCIB1+ Shows Improved Progression-Free Survival in Advanced Melanoma - Slideshow - Seeking Alpha